Trials / Completed
CompletedNCT01827852
AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung
AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,107 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (\<60, 60-69, 70-79, \>80 years) in patients with inoperable advanced, metastatic or recurrent adenocarcinoma non-small cell lung cancer. Patients will be followed for 18 months from the start of first-line therapy.
Conditions
Timeline
- Start date
- 2013-03-14
- Primary completion
- 2017-05-31
- Completion
- 2017-05-31
- First posted
- 2013-04-10
- Last updated
- 2017-07-28
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01827852. Inclusion in this directory is not an endorsement.